Liver biopsy in HIV-infected patients with chronic hepatitis C: Pros and cons

HIV Clinical Trials

Volumn 3, Issue 5, 2002, Pages 351-353

  Soriano, Vincent ^a   García Samaniego, Javier ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Biopsy; Hepatitis C; HIV; Liver; Treatment

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INTERFERON; RIBAVIRIN; ZIDOVUDINE;

ANEMIA; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG RESPONSE; EDITORIAL; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; PANCREATITIS; PRESCRIPTION; PRIORITY JOURNAL; SIDE EFFECT; SUPERINFECTION; TREATMENT PLANNING;

EID: 0036750085     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/v7xy-3ag9-75uv-ul69     Document Type: Editorial

References (39)

1. Brinkman K, ter Hofstede H. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: lactic acidosis, risk factors and therapeutic options. AIDS Rev. 1999;1:140-146.
2. García-Samaniego J, Soriano V, Castilla J, et al. Influence of HCV genotypes and HIV infection on histological severity of chronic hepatitis C. Am J Gastroenterol. 1997;92:1130-1134.
3. Benhamou Y, Bochet M, Di Martino V. Liver fibrosis progression in HIV and hepatitis C virus coinfected patients. Hepatology. 1999;30:1054-1058.
4. Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr. 2000;24:211-217.
5. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Infect Dis. 2001;32:492-497.
6. Monga H, Rodríguez-Barradas M, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with HIV infection. Clin Infect Dis. 2001;33:240-247.
7. Martín-Carbonero L, Soriano V, Valencia ME, Garcia-Samaniego J, López M, González-Lahoz J. Impact of chronic viral hepatitis on hospital admission and mortality in HIV-infected patients. AIDS Res Hum Retrovirus. 2001;17:1467-1471.
8. Hagan H, Thiede H, Weiss N, Hopkins S, Duchin J, Alexander E. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health. 2001;91:42-46.
9. Sulkowski M, Thomas D, Chaisson R, Moore R. Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. JAMA. 2000;283:74-80.
10. Saves M, Raffi F, Clevenbergh P, et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-contained antiretroviral regimen in HIV-infected patients. Antimicrob Agents Chemother. 2000;44:3451-3455.
11. Núñez M, Lana R, Mendoza JL, Martín-Carbonero L, Soriano V. Risk factors for severe liver toxicity following the introduction of HAART. J Acquir Immune Defic Syndr. 2001;27:426-431.
12. Eyster M, Diamondstone L, Lien J, et al. Natural history of HCV infection in multitransfused hemophiliacs: effect of coinfection with HIV. J Acquir Immune Defic Syndr. 1993;6:602-610.
13. Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol. 1994;87:555-561.
14. Soto B, Sánchez-Quijano A, Rodrigo L, et al. HIV infection modifies the natural history of chronic parenterally acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997;26:1-5.
15. Di Martino V, Rufat P, Boyer N, et al. The influence of HIV coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology. 2001;34:1193-1199.
16. Kjaergard L, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C. Systematic review of randomised trials. BMJ. 2001;323:1151-1155.
17. Zeuzem S, Feinman S, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666-1672.
18. Fried M. Pegasys and ribavirin for the treatment of chronic hepatitis C [abstract 2891]. Dig Dis Wkly. April 2001.
19. Manns M, McHutchison J, Gordon S, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.
20. Pérez-Olmeda M, Núñez M, Romero M, et al. Peginterferon plus ribavirin for chronic hepatitis C in HIV-infected patients. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Washington. Abstract 652.
21. Juárez A, Esteban JI, Sauleda S, et al. Randomised trial of Intron A and ribavirin versus Peg-Intron and ribavirin in HIV-HCV coinfected patients. Interim report on safety data [abstract 985]. Hepatology. 2001;34(suppl):418A.
22. Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV coinfection. Recommendations from the HIV-HCV International Panel. AIDS. 2002;16:813-828.
23. Saadeh S, Cammell G, Carey W, Younossi Z, Barnes D, Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology. 2001;33:196-200.
24. García G, Keeffe E. Liver biopsy in chronic hepatitis C: routine or selective. Am J Gastroenterol. 2001;96:3053-3055.
25. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996;23:1334-1340.
26. Poynard T. Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825-832.
27. NIH Consensus Development Conference. Management of chronic hepatitis C. Hepatology. 1997;26(suppl 1): 2-10.
28. EASL. International consensus conference on hepatitis C. J Hepatol. 1999;30:956-961.
29. Piccinino F, Sagnelli E, Pasquale G, et al. Complications following percutaneous liver biopsy. A multicenter retrospective study on 68,276 biopsies. J Hepatol. 1986;2:165-173.
30. Cadranel J, Rufat P, Degos F. Practices of liver biopsy in France. Results of a prospective nationwide survey. Hepatology. 2000;32:477-481.
31. Maharaj R, Leary W, Coppan R, Naran A, Pirie D, Pudufin D. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet. 1986;ii:523-525.
32. Wong J, Bennett W, Koff R, et al. Pre-treatment evaluation of chronic hepatitis C. Risks, benefits, and costs. JAMA. 1998;280:2088-2093.
33. Spinzi G, Minoli G. To biopsy or not to biopsy. Hepatology. 2001;34:438-439.
34. Andriulli A, Mangia A, Niro G, Caturelli E. To biopsy or not to biopsy. Hepatology. 2001;34:438.
35. García-Samaniego J, Soriano V, Miró JM, et al. Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference. HIV Clin Trials. 2002;3(2):99-114.
36. Churchill D, Mann D, Coker R, et al. Fatal haemorrhage following liver biopsy in patients with HIV infection. Genitourin Med. 1996;72:62-64.
37. Soriano V, García-Samaniego J, Bravo R, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with HIV. The Hepatitis-HIV Spanish Study Group. Clin Infect Dis. 1996;23:585-591.
38. Bonacini M, Puoti M. Hepatitis C in patients with HIV infection. Arch Intern Med. 2000;160:3365-3373.
39. Lafeuillade A, Hittinger G, Chapadaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet. 2001;357:280-281.